PLSENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

PULSE BIOSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$47.55+3.12 (+7.02%)

Close on Oct 19, 2026

Market cap: $3.29B
P/E (TTM): –
Dividend yield: –

PULSE BIOSCIENCES, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Stock-Based Compensation	21	14	7.18	5.19	15	10	11	12	11	0.87	0.40
Deferred Income Taxes	–	–	0	0	0	0	–	–	–	–	-1.66
Change in Accounts Receivable	-0.27	0	0	0.06	-0.06	0	–	–	–	–	–
Change in Inventory	-0.14	0	0	-2.65	-5.82	0	–	–	–	–	–
Change in Accounts Payable	1.13	-0.20	0.26	-1.30	1.16	-0.27	0.65	0.49	0.52	0.00	0.13
Change in Unearned Revenue	–	–	0	-0.02	0.02	0	–	–	–	–	-0.04
Operating Cash Flow	-54	-36	-33	-47	-54	-35	-34	-24	-11	-8.05	-3.32
Capital Expenditures	-0.32	-0.13	-0.12	-0.40	-0.44	-0.44	-0.61	-0.28	-2.55	-0.06	-0.09
Purchase of Investments	–	–	–	0	0	-29	-78	-40	-44	-19	–
Sale & Maturity of Investments	–	–	–	0	8.00	4.51	69	25	23	4.75	–
Investing Cash Flow	-0.34	-0.13	-0.12	-0.40	7.56	10	-10	26	-23	-14	-0.09
Stock Issued	–	–	0	15	57	29	–	–	–	–	–
Debt Issued	–	–	–	0	1.94	0	–	–	–	–	–
Debt Repaid	–	–	0	-0.44	-1.53	0	–	–	–	–	–
Taxes Paid on Share-Based Awards	–	–	–	0	-0.23	0	-0.61	-0.12	–	–	–
Financing Cash Flow	17	110	16	80	63	31	0.08	45	35	21	–
Net Change in Cash	-37	74	-17	33	16	5.56	–	48	1.30	-1.52	-3.40
Free Cash Flow	-54	-36	-33	-47	-55	-36	-35	-24	-14	-8.12	-3.40

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 0.3%
Operating margin: -7007.8%
Net margin: -6755.8%
Return on equity, FY2025: -74.4%

Financial strength

Current ratio: 9.63
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 925.7%

Valuation

P/E ratio: –
Price to sales: 2776.76
Price to book: 33.07
Dividend yield: –